Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparable survival outcomes after myeloablative allogeneic stem cell transplantation in secondary and de novo Acute Myeloid Leukemia in first complete remission: A propensity Score–Matched study

View Full Paper
Ask AI
Bookmark
Share

Authors

DFDan Feng

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows comparable survival in secondary and de novo AML after transplantation, suggesting similar treatment efficacy.

Key Points

  • This research examines survival outcomes after myeloablative allogeneic stem cell transplantation in patients with secondary and de novo acute myeloid leukemia (AML).
  • Retrospective, single-center analysis at a hematology hospital.
  • Included adults diagnosed with either secondary or de novo AML receiving first allogeneic hematopoietic stem cell transplantation.
  • Evaluated transplant outcomes, including graft-versus-host disease and overall survival rates.
  • No significant differences in engraftment rates between sAML and de novo AML groups.
  • Two-year overall survival rates were similar: 67.9% for de novo AML and 66.6% for sAML.
  • Incidences of grade II–IV acute GVHD were comparable in both groups.

Cite This Study

Dan Feng (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d726https://doi.org/10.1182/blood-2025-7741
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparable survival outcomes for secondary and de novo acute myeloid leukemia after haploidentical hematopoietic stem cell transplantation2026
  2. 2Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT2024 · 7 citations
  3. 3Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary <scp>AML</scp> in First Complete Remission: A Study From the <scp>ALWP</scp> / <scp>EBMT</scp>2025 · 5 citations
  4. 4T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  5. 5Good report of secondary allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Myeloid Leukemia2025